Metrics as of 10/15/2026, 03:49 AM (Berlin time), refresh in progress.
Parabilis Medicines Stock
Parabilis Medicines, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Mathai Mammen
- Employees
- 145
- Market cap
- $3.2 B
- IPO
- 10/06/2026
Parabilis Medicines, Inc. is a clinical-stage pharmaceutical company headquartered in Cambridge, USA. The company was founded in 2015 by Gregory L. Verdine, WeiQing Zhou and David Philip Lane. Its core business model focuses on the discovery and development of cell-penetrating miniproteins (CPMPs). These proteins are…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Parabilis Medicines stock: price history
1D
-3.6%
1W
-10.2%
1M
-28.4%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Ask the agents about Parabilis Medicines
Analyst assessment of Parabilis Medicines
PRICE TARGET LOW
US$40.00
CONSENSUS
US$40.00
MEDIAN
US$40.00
PRICE TARGET HIGH
US$40.00
No current analyst ratings available.
Parabilis Medicines stock metrics
P/E
-0.7
P/B
0.71
EV/EBITDA
-22.04
RETURN ON EQUITY
-5.0%
NET MARGIN
-35,448.0%
DEBT/EQUITY
0.05
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
76.4%
FLOAT SHARES
89,058,129
AVG. DAILY VOLUME (30D)
1,102,435
Insider transactions (SEC)
RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P.
Institutional holders
Comparable stocks
Frequently asked questions about Parabilis Medicines stock
What does Parabilis Medicines do?
Parabilis Medicines, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Mathai Mammen, the company employs around 145 people.
The IPO was on 10/06/2026; the stock trades on NASDAQ under the ticker PBLS.
What do analysts say about Parabilis Medicines stock?
The average price target is US$40.00, ranging from US$40.00 to US$40.00, with a median of US$40.00.
This is an external assessment, not a statement by Market Jury.
Does Parabilis Medicines pay a dividend?
No, Parabilis Medicines currently does not pay a dividend.
Which stocks are comparable to Parabilis Medicines?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Parabilis Medicines stock analyzed?
Clicking "Analyze stock" lets five strategies assess Parabilis Medicines against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.